1. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
2. Woodcock, J. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development (US Food and Drug Adminisration, Rockville, MD, 2004).
http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2_03_Woodcock_files/frame.htm
3. Rubenstein, K. Post-genomic biomarkers: revolutionizing drug development and diagnostics (D&MD Publications, Westborough, MA, 2003).
4. Wei, C.-M. et al. Endothelin in human congestive heart failure. Circulation, 89, 1580–1586 (1994).
5. De Meyer, G. & Shapiro, F. Biomarker development: the road to clinical utility. Current Drug Discovery 12, 23–27 (2003).